# Rumble

Type: Company (RUM)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/rumble
Canonical HTML page: https://gethealthbrief.com/entity/rumble

## Timeline

- **2026-03-05**: Earnings Release — Companies report Q4 and Full Year 2025 results, signaling a shift to 2026 commercial targets.
- **2025-12-31**: Fiscal Year End — Med-tech firms report record system utilization rates for the 2025 calendar year.
- **2025-06-20**: Clinical Enrollment — Atea Pharmaceuticals completes enrollment for the Phase 2 Hepatitis C (HCV) trial.
- **2025-03-15**: Reimbursement Milestone — Profound Medical receives expanded CPT code coverage for TULSA-PRO in the U.S.

## Recent coverage (2 stories)

### CooperCompanies Hits Q4 Targets Amid Steady Vision and Surgical Demand
2026-03-05 23:28:19 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

CooperCompanies (NASDAQ: COO) reported fourth-quarter 2025 financial results that met analyst expectations, driven by consistent performance across its CooperVision and CooperSurgical business units. The results underscore the company's resilience in the medical device sector despite broader macroeconomic fluctuations.
Full story: https://gethealthbrief.com/story/coopercompanies-q4-2025-earnings-analysis

### MedTech and Biotech Earnings: Profound Medical and Atea Signal 2026 Pivot
2026-03-05 22:41:33 · Sentiment: Neutral · Impact: 5/10 · Sources: 5

Atea Pharmaceuticals and Profound Medical headlined a series of Q4 2025 earnings reports, highlighting a shift toward commercial scaling in medical devices and late-stage clinical milestones in biotech. These results underscore a sector-wide focus on capital preservation and high-margin recurring revenue models.
Full story: https://gethealthbrief.com/story/medtech-biotech-earnings-q4-2025-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.